Latest Earnings Results: Q3 '26
Estimated EPS
-$0.21
Reported EPS
-$0.23
Surprise
-7.33%
Estimated Rev
$0M
Reported Rev
---
Surprise
---
Whitehawk Therapeutics believes its $169.7M in cash, cash equivalents and short-term investments will enable planned operations into the second half of 2028, and does not expect revenue for the foreseeable future.
Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q4 '26 | -$0.22 | -- | -- | N/A |
Q3 '26 | -$0.21 | -$0.23 | -7.33% | MISSED |
Q2 '26 | -$0.30 | -$0.20 | 32.37% | BEAT |
Q1 '26 | -$0.36 | -$0.32 | 10.49% | BEAT |
Q4 '25 | -$0.48 | -$0.34 | 29.55% | BEAT |